• Home
  • Insights & Publications
  • Case studies
  • 2015
  • Implementing a new product and innovation (NPI) framework for a global consum...

Implementing a new product and innovation (NPI) framework for a global consumer health business

We designed improvements to the new product and innovation (NPI) framework for this global consumer healthcare business. Moorhouse implemented a ‘stage-gated’ framework, which improved the speed that new products were developed and could be taken to market while ensuring delivery risk was controlled.

The challenge to the client


A global consumer healthcare organisation set about expanding their fast-moving consumer healthcare (FMCH) function with the goal of becoming the leading company in this market. Crucial to this strategy was the creation of a new product development process that would be lean, efficient and enable the biggest ‘bang for buck’ when developing and launching new products. 

Our approach

We were engaged to support the design of improvements to the NPI framework. The team led key client stakeholders through an analysis of the current framework and took an agile approach to developing a working prototype of a new improved framework. Central to the new framework was a robust project categorisation tool, built by our team, along with an appropriate governance layer to enable effective faster decision making. To support a controlled roll-out of the framework we also developed an implementation roadmap and delivery plan.

Value to the client

Our work helped deliver rapid improvements to the design of the NPI framework and the approach adopted by our team improved cross-functional collaboration across the programme. The implementation plan enabled our client to realise its strategic goals of improved speed to market, improved control of delivery risk and increased return on innovation investment. The transition to the new framework was seemless.

Similar case studies


Helping a global pharmaceutical organisation manage its portfolio

Read more

Test tubes

Working on an integration, partnership and divestment between two global pharmaceutical firms

Read more